Compare Freeport-McMoRan Inc (FCX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Johnson & Johnson — how do they compare? Freeport-McMoRan Inc trades at $73.32 (market cap $102.16B), while Johnson & Johnson trades at $258.73 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 6.1× Freeport-McMoRan Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Johnson & Johnson for 129 Days on average.
| FCX | JNJ | |
|---|---|---|
Market Cap | $102.16B | $618.09B |
Volume | 9,047,971 | 6,050,983 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $278.43 |
52-Week Low | $38.65 | $186.00 |
Typical Hold Time | 69 Days | 129 Days |
Enterprise Value | $108.44B | $646.37B |
Dividend Yield | 0.84% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.87, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $73.27. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $25.92 billion, with net income of $2.20 billion and a net margin of 11.38%. Recent news highlights strong copper demand driven by AI and data center growth, positioning FCX to benefit from favorable market trends.
The outlook for FCX is positive, supported by robust copper demand and expansion projects, but risks include rising production costs and potential regulatory investigations. Analyst sentiment is predominantly bullish, with 61% recommending buy. The stock offers growth potential from commodity tailwinds, though investors should monitor cost pressures and execution of growth initiatives.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
